JP2021507707A5 - - Google Patents

Info

Publication number
JP2021507707A5
JP2021507707A5 JP2020534373A JP2020534373A JP2021507707A5 JP 2021507707 A5 JP2021507707 A5 JP 2021507707A5 JP 2020534373 A JP2020534373 A JP 2020534373A JP 2020534373 A JP2020534373 A JP 2020534373A JP 2021507707 A5 JP2021507707 A5 JP 2021507707A5
Authority
JP
Japan
Prior art keywords
protein
nucleic acid
mev
acid construct
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020534373A
Other languages
English (en)
Japanese (ja)
Other versions
JP7841847B2 (ja
JP2021507707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/001620 external-priority patent/WO2019123018A2/en
Publication of JP2021507707A publication Critical patent/JP2021507707A/ja
Priority to JP2023192505A priority Critical patent/JP2024009058A/ja
Publication of JP2021507707A5 publication Critical patent/JP2021507707A5/ja
Application granted granted Critical
Publication of JP7841847B2 publication Critical patent/JP7841847B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020534373A 2017-12-21 2018-12-20 ラッサワクチン Active JP7841847B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023192505A JP2024009058A (ja) 2017-12-21 2023-11-10 ラッサワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609155P 2017-12-21 2017-12-21
US62/609,155 2017-12-21
PCT/IB2018/001620 WO2019123018A2 (en) 2017-12-21 2018-12-20 Lassa vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023192505A Division JP2024009058A (ja) 2017-12-21 2023-11-10 ラッサワクチン

Publications (3)

Publication Number Publication Date
JP2021507707A JP2021507707A (ja) 2021-02-25
JP2021507707A5 true JP2021507707A5 (cg-RX-API-DMAC7.html) 2026-01-26
JP7841847B2 JP7841847B2 (ja) 2026-04-07

Family

ID=65763665

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020534373A Active JP7841847B2 (ja) 2017-12-21 2018-12-20 ラッサワクチン
JP2023192505A Withdrawn JP2024009058A (ja) 2017-12-21 2023-11-10 ラッサワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023192505A Withdrawn JP2024009058A (ja) 2017-12-21 2023-11-10 ラッサワクチン

Country Status (11)

Country Link
US (1) US11976305B2 (cg-RX-API-DMAC7.html)
EP (1) EP3727411A2 (cg-RX-API-DMAC7.html)
JP (2) JP7841847B2 (cg-RX-API-DMAC7.html)
KR (1) KR102822230B1 (cg-RX-API-DMAC7.html)
CN (1) CN111886342B (cg-RX-API-DMAC7.html)
AU (1) AU2018392826B2 (cg-RX-API-DMAC7.html)
CA (1) CA3085224A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020006476A (cg-RX-API-DMAC7.html)
SG (1) SG11202004899SA (cg-RX-API-DMAC7.html)
WO (1) WO2019123018A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202003070B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111206022A (zh) * 2020-02-20 2020-05-29 中国人民解放军军事科学院军事医学研究院 一种表达拉沙热病毒空衣壳的重组病毒及其制备方法
KR102404143B1 (ko) * 2020-04-21 2022-05-31 대한민국(질병관리청장) 라싸 바이러스 핵단백질에 특이적인 항체, 이를 생산하는 하이브리도마 세포주 및 이를 이용한 라싸 바이러스 검출 키트
TWI815572B (zh) * 2021-09-27 2023-09-11 美商圖策智能科技有限公司 特定病毒的突變耐受表位的推估方法及系統
WO2026013289A1 (en) * 2024-07-12 2026-01-15 Institut Pasteur Measles-mumps-rubella (mmr) vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0780475B2 (en) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
EP1375512B1 (en) * 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
AU2004262022B2 (en) * 2003-08-01 2010-10-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Accelerated vaccination
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
US20120219576A1 (en) 2009-09-16 2012-08-30 The Administrators Of The Tulane Educational Fund Lassa virus-like particles and methods of production thereof
KR102314421B1 (ko) * 2011-07-11 2021-10-19 이노비오 파마수티컬즈, 인크. 교차-보호성 아레나바이러스 백신 및 이의 사용 방법
US11701418B2 (en) * 2015-01-12 2023-07-18 Geovax, Inc. Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
EP3103474A1 (en) * 2015-06-12 2016-12-14 Institut Pasteur Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses

Similar Documents

Publication Publication Date Title
RU2733834C1 (ru) Искусственный ген EctoS_SC2, кодирующий эктодомен гликопротеина S коронавируса SARS-CoV-2 с C-концевым тримеризующим доменом, рекомбинантная плазмида pStem-rVSV-EctoS_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-EctoS_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2
AU2001293222B2 (en) Packaging of positive-strand RNA virus replicon particles
CA2343653A1 (en) Recombinant newcastle disease virus rna expression systems and vaccines
JP2010530245A5 (cg-RX-API-DMAC7.html)
EP2900687B1 (en) Recombinant measles virus expressing chikungunya virus polypeptides and their applications
JP2018186815A5 (cg-RX-API-DMAC7.html)
JP2019530466A5 (cg-RX-API-DMAC7.html)
JP2017536116A5 (cg-RX-API-DMAC7.html)
CN107921117A (zh) Hpv疫苗
JP2017535267A5 (cg-RX-API-DMAC7.html)
JP2004501646A5 (cg-RX-API-DMAC7.html)
JP2023523414A5 (cg-RX-API-DMAC7.html)
IL275427B1 (en) Hepatitis b virus (hbv) vaccines and uses thereof
Atasheva et al. Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation
JP2023525785A (ja) 安定化コロナウイルススパイクタンパク質をコードするrnaレプリコン
JP2025169275A5 (cg-RX-API-DMAC7.html)
JP2014519817A5 (cg-RX-API-DMAC7.html)
ES2585735T3 (es) Nuevas proteínas de fusión y su aplicación para la preparación de vacunas contra la hepatitis C
CN111218477B (zh) 靶向感染哺乳动物细胞的禽4型腺病毒载体及其应用
EP3158060B1 (en) Method for rapid generation of an infectious rna virus
EP3865180A1 (en) Live recombinant measles virus expressing coronavirus antigens - its use in eliciting immunity against coronaviruses
JP2011507515A5 (cg-RX-API-DMAC7.html)
AU2018392826A1 (en) Lassa vaccine
KR20160025553A (ko) 세미-라이브 호흡기 세포융합 바이러스 백신
JP2024542126A5 (cg-RX-API-DMAC7.html)